Registry of Lobbyists

Registration - In-house Corporation

Pfizer Canada ULC / Najah Sampson, President

Registration Information

In-house Corporation name: Pfizer Canada ULC
Responsible Officer Name: Najah Sampson, President 
Responsible Officer Change History
Initial registration start date: 2007-04-27
Registration status: Active
Registration Number: 951977-15283

Associated Communications

Total Number of Communication Reports: 284

Monthly communication reports in the last 6 months: 4

Version 1 of 34 (2007-04-27 to 2007-11-08)

Version 1 of 34 (2007-04-27 to 2007-11-08) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Pfizer Canada ULC
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QC  H9J 2M5
Canada
Telephone number: 514-426-7417
Fax number: 514-426-6835  
Responsible officer name and position during the period of this registration: Paul Lévesque, Président et chef de la direction  
Description of activities: Research, development, manufacture, marketing and sale of pharmaceuticals, animal health products.
 
The client is a subsidiary of the following parent companies: PFIZER INC
235 EAST 42ND STREET
NEW YORK, NY
United States of America 10017-5755

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: John Carkner
Position title: Site Leader, Technical Director
Public offices held: No
 
Name: Nicolas Gagnon
Position title: Manager, Pricing
Public offices held: Yes
 
Name: Vratislav Hadrava
Position title: Director, Regulatory Affairs & Safety
Public offices held: No
 
Name: John Helou
Position title: Vice President, Public Affairs & Stakeholder Relations
Public offices held: No
 
Name: Steven Hogue
Position title: Manager, Federal Relations
Public offices held: Yes
 
Name: Maria Klapka
Position title: Director, Regulatory Policy & Intelligence
Public offices held: No
 
Name: Paul Lévesque
Position title: President & CEO
Public offices held: No
 
Name: David Malian
Position title: Director, Government & Professional Affairs
Public offices held: No
 
Name: Madeleine Pesant
Position title: Associate Director, Regulatory Policy & Intelligence
Public offices held: No
 
Name: Bernard Prigent
Position title: Vice President and Medical Director
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Agriculture and Agri-Food Canada (AAFC), Competition Tribunal (CT), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Immigration and Refugee Board (IRB), Industry Canada, National Defence (DND), Office of the Information and Privacy Commissioner (OIPC), Parliament, Patented Medicine Prices Review Board (PMPRB), Privy Council Office (PCO), Revenue Canada (RC), Royal Canadian Mounted Police (RCMP), Solicitor General Canada (SGC), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Other types: As part of Industry Associations and Delegations eg. Rx&D, BIOTECanada, Chamber of Commerce, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Affairs, Access to Information, Agriculture, Competition Law, Consumer Issues, Cross-border Trade, Education, Environment, Federally-funded Health Benefits Program, Health, Immigration, Industry, Intellectual Property, Inter-governmental Affairs, Internal Trade, International Trade, Pharmaceutical Pricing Regulation, Regional Development, Research Funding, Research Policies, Regulations and Ethnics, Science and Technology, Taxation and Finance, Veterans Affairs (Medication Procurement, Health Partnership, Pharmaceutical Policy), Veterinary Biologics, Veterinary Drugs
 
Subject Matter: Retrospective: Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants.
Subject Matter: Prospective: Informal communications, phone calls, written communications, meetings, presentations with: ministers, members of parliament, senators, political advisors and civil servants.
 

Details Regarding the Identified Subject Matter

Categories Description
Regulation, Legislative Proposal Access to Information Act & Regulations
Policy or Program Adverse Event Reporting Policies
Policy or Program Auditor General Reports
Policy or Program Broad Pharmaceutical Policy Approaches
Regulation Canadian Access to Medicines Regime (consultations)
Policy or Program Canadian Institute of Health Researchers (CIHR) and other Research Oriented Spending Programs
Policy or Program Canadian Strategy for Cancer Control
Policy or Program Clinical Assessment of Abuse Liability for Drugs with Central Nervous System (CNS) Activity-Draft Guidance
Policy or Program Clinical Evaluation of QT/QTc Interval Prolongation & Proarrhythmic Potential for Non-Antarrythmic Drugs-Adoption of International Conference on Harmonization (ICH) Guidelines (Health Canada document: QT/QTc Interval Prolongation: Guidance for Product Monograph Content or see: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/qtqtc/qt_pm_mp_e.html#1)
Regulation Clinical Trials Regulations (Division 5)
Policy or Program, Legislative Proposal Competition Act Amendments
Policy or Program Cost Recovery & Performance
Policy or Program Cross Border Trade
Regulation Data Protection/Patented Medicines Notice of Compliance Regulations [PM(NOC) Regulations]
Policy or Program Department of National Defense Health Benefits Program
Grant, Contribution or Other Financial Benefit Donations by Corporations of Property held in inventory (donation of pharmaceutical products)
Regulation Draft 2007 Good Manufacturing Practices (GMPs)
Legislative Proposal Drug Product Review & Approval System
Regulation Drug Product Review & Approval System / Regulations (filing formats of drug submissions, i.e. electronic Common Technical Document (eCTD) providing review tools currently not listed in the regulations)
Policy or Program Drug Safety
Policy or Program Drugs Review & Approval Systems (Improving the efficiency of over-the-counter and natural health products)
Policy or Program Federal/Provincial/Territorial Pharmaceutical Management Initiative: Canadian Agency for Drugs and Technologies in Health (CADTH)
Policy or Program Federal/Provincial/Territorial Pharmaceutical Management Initiative: Canadian Expert Drug Advisory Committee (CEDAC) )
Policy or Program Federal/Provincial/Territorial Pharmaceutical Management Initiative: Canadian Optimal Medication Prescribing and Utilization Service (COMPUS)
Policy or Program Federal/Provincial/TerritorialPharmaceutical Management Initiative: Common Drug Review (CDR)
Policy or Program Federal/Provincial/Territorial Pharmaceutical Management Initiative: National Prescription Drug Utilization Information System (NPDUIS)
Bill or Resolution, Regulation Federal Accountability Act
Policy or Program Food & Drug Act & Regulatory Policies - Good Manufacturing Practices and Establishment Licensing
Regulation Food & Drug Regulations (Good Manufacturing Practices & Establishment Licensing)
Regulation Food & Drugs Act (Drug Review & Approval regulations, Amendments to FDA, Data protection, Direct-to-Consumer Advertising Regs, New Substance Notification Regulations, Clinical Registry and Disclosure Regulation, GMP & Establishment Licensing)
Legislative Proposal Food and Drugs Act (Cross Border Trade [CBT], Drug Export Restrictions, Regulatory Policies)
Policy or Program Health Canada Memorandum of Understanding with the US Food and Drugs Administration
Policy or Program Health Canada Non-insured Health Benefits Program
Policy or Program Health Canada Pharmaceutical and Biological Policies and Applicable Guidelines
Policy or Program Health Canada Pharmaceutical Policies and Guidelines
Policy or Program Health Canada Probationary / Progressive Licensing Framework
Policy or Program Health Canada Subsequent Entry Biologics Policy
Policy or Program Health Canada Therapeutic Access Strategy
Legislative Proposal Health Protection Act (Legislative Renewal)
Policy or Program Health Protection and Food Branch External Changing Program
Policy or Program Health Research Funding
Policy or Program Improving the efficiency of the drug review and approval process
Policy or Program Innovation Agenda
Policy or Program Management of Submission Poilcy
Policy or Program National Pharmaceutical Strategy
Legislative Proposal Patent Act
Regulation Patent Act (NoC Linkage) Regulations
Regulation Patent Act (Patented Medicines (Notice of Compliance)) Regulations - Amendments to
Regulation, Bill or Resolution Patented Medicine Prices Review Board (PMPRB) Regulations
Policy or Program Patent Policies
Legislative Proposal Personal Information Protection and Electronic Documents Act
Policy or Program Personal Use Importation of Products for Livestock Production
Policy or Program Pharmacogenomics/Biomarkers
Policy or Program, Regulation PMPRB (Patented Medicine Prices Review Board) (Appointment policies/guideline changes/regulations)
Legislative Proposal Pre-Budget Consultations
Legislative Proposal Privacy Act
Policy or Program Proposed Clinical Trials Registry-Disclosure
Policy or Program Public Service Health Care Plan
Policy or Program Royal Canadian Mounted Police National Health Services
Policy or Program Science and Technology Policy
Policy or Program Smart Regulations (Specific, measurable, attainable, realistic, timelines Regulations)
Policy or Program Trade (related to border opening for live cattle for reproduction)
Policy or Program Vaccine Review and Approval System (Canadian Food Inspection Agency)
Regulation Vet Biologics Regulatory Reveiw (CFIA) - New Product Licensing Guidelines, Licensing of United States Department of Agriculture approved products for companion animals
Regulation Vet Biologics Regulatory Review (Canadian Food Inspection Agency (CFIA)) - New product Licensing Guidelines
Regulation Vet Biologics Regulatory Review (Canadian Food Inspection Agency) - Conditional Licensing Guidelines
Policy or Program Veterans Affairs Drug Benefits Plan
Legislative Proposal Veterinary Drug Distribution (VDDs) Document on Antimicrobial Categorization




Date Modified: